Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antimicrobials
Second study to test persistency of chlorhexidine hand sanitizer commissioned in Europe
February 27th, 2006
Skinvisible, Inc. (SKVI) announced that it is commissioning a second study by Retroscreen Virology Ltd., a European contract virology research company, of Skinvisible's patent-pending chlorhexidine hand sanitizer, developed by its wholly owned subsidiary, Skinvisible Pharmaceuticals. The first study results demonstrated that the hand sanitizer had a greater than 99% kill on the bird flu virus (H5N1) at four time points of 15 seconds, 30 seconds, 1 minute and 5 minutes. The purpose of the second study, expected to be completed within 6 weeks, is to quantify the 'persistency' of the chlorhexidine hand sanitizer, i.e., demonstrate that its patented delivery system,...
Source: Pharma Business Week (2006-02-27)
|
